An Open-Label, Phase 1/2 Study on safety and effectiveness of RAD001 in Subjects with Myelofibrosis sponsored by Associazione italiana del Farmaco (AIFA).

Trial Profile

An Open-Label, Phase 1/2 Study on safety and effectiveness of RAD001 in Subjects with Myelofibrosis sponsored by Associazione italiana del Farmaco (AIFA).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 25 May 2011 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
    • 15 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top